A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Conditions: NASH/MASH; NAFLD/MASLD Interventions: Drug: Efruxifermin; Drug: Placebo Sponsors: Akero Therapeutics, Inc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials